freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
=== Intramucosal nevi === An intramucosal nevus is a nevus within the mucosa as found in for example the mouth and genital areas. In the mouth, they are found most frequently on the hard palate. They are typically light brown and dome-shaped. Intramucosal nevi account for 64% of all reported case of oral nevi.
Droplet-based microfluidics is differs from continuous microfluidics; droplet-based microfluidics manipulates discrete volumes of fluids in immiscible phases with low Reynolds number and laminar flow regimes. Interest in droplet-based microfluidics systems has been growing substantially in past decades. Microdroplets allow for handling miniature volumes (μL to fL) of fluids conveniently, provide better mixing, encapsulation, sorting, and sensing, and suit high throughput experiments. Exploiting the benefits of droplet-based microfluidics efficiently requires a deep understanding of droplet generation to perform various logical operations such as droplet manipulation, droplet sorting, droplet merging, and droplet breakup.
The membership of the PSC was reduced from nine to seven, with Xi and Li Keqiang retaining their seats; the other five members were new. In December 2012, Xi visited Guangdong in his first trip outside Beijing since taking the general secretaryship. The overarching theme of the trip was to call for further economic reform and a strengthened military. Xi was elected president on 14 March 2013, in a confirmation vote during the first session of the 12th National People's Congress in Beijing. He received 2,952 for, one vote against, and three abstentions. He replaced Hu Jintao, who retired after serving two terms. Xi was also elected as the chairman of the state CMC. He subsequently nominated Li Keqiang to be the premier, who was then appointed by the NPC.
Previously, there had been no detailed descriptions of their spectral properties in peer-reviewed general scientific literature. A small amount of agent A-230 was also claimed to have been synthesised in the Czech Republic in 2017 for the purpose of obtaining analytical data to help defend against these novel toxic compounds. The Soviet Union and Russia reportedly developed extremely potent fourth-generation chemical weapons from the 1970s until the early 1990s, according to a publication by two chemists, Lev Fyodorov and Vil Mirzayanov, in Moskovskiye Novosti weekly in 1992. The publication appeared just on the eve of Russia's signing of the Chemical Weapons Convention. According to Mirzayanov, the Russian Military Chemical Complex (MCC) was using defence conversion money received from the West for development of a chemical warfare facility. Mirzayanov made his disclosure out of environmental concerns. He was the head of a counter-intelligence department and performed measurements outside the chemical weapons facilities to make sure that foreign spies could not detect any traces of production. To his horror, the levels of deadly substances were eighty times greater than the maximum safe concentration. The Prosecutor-General of Russia effectively admitted the existence of Novichok agents when he brought a treason case against Mirzayanov. According to expert witness testimonies that three scientists prepared for the KGB, Novichok and other related chemical agents had indeed been produced and therefore Mirzayanov's disclosure represented high treason.
Sources: en.wikipedia.org
== Professional career == Esimone started his career as internee pharmacist and then became a laboratory instructor, all in the Department of Pharmaceutics, University of Nigeria Nsukka. He became a professor of biopharmaceutics and pharmaceutical microbiology at the age of 37 years and was the pioneer Dean, Faculty of Pharmaceutical Sciences, Agulu Campus of Nnamdi Azikiwe University Awka. He also served two terms of 2 years each as the Deputy Vice-Chancellor (Academics) of Nnamdi Azikiwe University, Awka. He is a researcher with well over 100 publications and in May 2019 was ranked 18th on the list of 28 Most Published Scholars in Nigeria. Prof. Esimone was also the Director of Confucius Institute of Nnamdi Azikiwe University, Awka. On the 14 of May 2019 he was elected the new Vice Chancellor of Nnamdi Azikiwe University, Awka. He is the State Campus Coordinator for Deeper Life Campus Fellowship, Anambra State and also a member, BOT (Board of Trustees) of Anchor University, Lagos.
=== CNO-I === The first proposed catalytic cycle for the conversion of hydrogen into helium was initially called the carbon–nitrogen cycle (CN-cycle), also referred to as the Bethe–Weizsäcker cycle in honor of the independent work of Carl Friedrich von Weizsäcker in 1937–38 and Hans Bethe. Bethe's 1939 papers on the CN-cycle drew on three earlier papers written in collaboration with Robert Bacher and Milton Stanley Livingston and which came to be known informally as Bethe's Bible. It was considered the standard work on nuclear physics for many years and was a significant factor in his being awarded the 1967 Nobel Prize in Physics. Bethe's original calculations suggested the CN-cycle was the Sun's primary source of energy. This conclusion arose from a belief that is now known to be mistaken, that the abundance of nitrogen in the sun is approximately 10%; it is actually less than half a percent. The CN-cycle, named as it contains no stable isotope of oxygen, involves the following cycle of transformations:
=== Immune checkpoint inhibitors === Because of HLA-G's role in inhibiting NK cell responses in cancer, clinical immune checkpoint inhibitors targeting HLA-G have been designed. Tizona Therapeutics developed TTX-080, a monoclonal antibody targeting HLA-G's interaction with ILT2 and ILT4. In 2020, a phase 1a/1b trial began to assess safety and preliminary efficacy in multiple cancers. Early results showed activity in HPV-negative HNSCC and HER2-negative metastatic colorectal cancer with WT RAS/BRAF, leading to an expansion of the trial.
Sources: en.wikipedia.org
=== Forensics === BRT's Forensics division offers services in serology screening, DNA profiling, and case review. These services are contracted by government agencies, defense counsel, and private citizens or organizations for several applications. Government agencies contract BRT’s Forensic division for criminal and “no-suspect” casework. The Laboratory offers STR analysis and Y-STR analysis with each of the commercial kits commonly used in the US. The Forensic division is accredited by ASCLD/Lab – International and meets the requirements of ISO/IEC 17025. BRT has also received accreditation from the Texas Department of Public Safety and has been approved by the Maryland State Police Forensic Science Division for analysis of casework that can be uploaded to CODIS. The Laboratory adheres to current Scientific Working Group on DNA Analysis Methods (SWGDAM) and FBI DNA Advisory Board (DAB) guidelines. Defense counsel contract BRT Laboratories to perform case reviews, which may include assistance with the interpretation of subpoena documents, sample retesting, and/or expert witness testimony. The Forensic division also provides serology and DNA profiling services to private citizens for infidelity testing and to private organizations or medical professionals for sample identity verification.
When dense-core vesicles are triggered, they release the stored information into the blood or extracellular space, resulting in amyloid disassembly, in order for action. Therefore, for these types of peptides, reversibility of peptide aggregation is essential for their function.
A fleet of opium clippers on the River Ganges Confessions of a Poppy Tea addict DEA drug information: Opium, morphine, and heroin From Flowers to Heroin, CIA publication Erowid: Opium Opium in India Opium Made Easy by Michael Pollan (originally appeared in Harper's.) House of Opium museum BLTC Research: Speculations on the future of opioids Thailex photo: Traditional method of using opium in Thailand Tsur Shezaf, Writer, The Opium Growers of Sinai Archived November 20, 2009, at the Wayback Machine UNODC – United Nations Office on Drugs and Crime – Afghan Opium Survey 2009 "The Alkaloids of Opium", Scientific American, 20 July 1878, p. 36, historical account on the physiological effects of the first 16 known alkaloids
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.